CARP applauds decision to add Lucentis to Ontario drug plan

About AMD

AMD is the leading cause of blindness in Canada. It affects one million Canadians – more than breast cancer, prostate cancer, Parkinson’s and Alzheimer’s disease combined.

Wet AMD is the most aggressive and devastating form of the disease, responsible for 90 per cent of the severe vision loss associated with AMD. People with wet AMD typically lose their central vision, which removes their ability to read, drive and identify faces of loved ones.

Approximately 10,000 patients are treated for AMD in Ontario each year.


For more information on Lucentis, visit the Ministry of Health and Long-Term Care.